Clinical trialPhase 1Completed
APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery
Safety and Immunologic Activity of Multiple Infusions of APN401
- Outcome
- Results posted; single-arm, no comparison
- Phase
- Phase 1
- Status
- Completed
- Study type
- Interventional
- Start
- 28 April 2017
- Ended
- 8 December 2020
- Enrollment
- 11 participants
- Sites
- 1
- Primary outcomes
- Number of Adverse Events Common Terminology Criteria for Adverse Events Version 4.0
- Sponsor type
- Academic / other
- Results posted
- 10 October 2024
- Last update
- 10 October 2024
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Results
- Primary endpoint
- Results posted; single-arm, no comparisonAs posted on ClinicalTrials.gov ↗, registry record of 10 October 2024
- Primary outcome
- Number of Adverse Events Common Terminology Criteria for Adverse Events Version 4.0General disorders and administration site conditions / Unobserved: Treatment (APN401): 0 of 9General disorders and administration site conditions / Grade 1: Treatment (APN401): 1 of 9General disorders and administration site conditions / Grade 2: Treatment (APN401): 8 of 9General disorders and administration site conditions / Grade 3: Treatment (APN401): 0 of 9Nervous System Disorders / Unobserved: Treatment (APN401): 5 of 9Nervous System Disorders / Grade 1: Treatment (APN401): 4 of 9Values: ParticipantsTime frame: Up to 1 year6 of 16 rows shownNo analysis posted for this outcome (outcome 1)
- Participants
- Treatment (APN401): 11 started, 9 completed
- Serious adverse events
- Treatment (APN401): 2 of 9Participants with at least one serious adverse event, of those at risk, as posted
6 secondary outcomes
- Clinical Response as Assessed by RECIST
- Complete Response: Treatment (APN401) 0/9 [Participants] (first of 4 rows)
- Frequency of Immune Cells
- CD3+ (day 15): Treatment (APN401) 37.1 (17.3), n=9 [mean percentage of cells, Standard Deviation] (first of 24 rows)
- Immune Response as Measured by Interferon Production
- IFN (day 15): Treatment (APN401) 75.1 (17.6), n=9 [mean pg/ml, Standard Deviation] (first of 4 rows)
- Neutrophil to Lymphocyte Ratio
- Day 15: Treatment (APN401) 2.72 (1.21), n=9 [mean ratio, Standard Deviation] (first of 2 rows)
- OS · Overall Survival (OS)
- Treatment (APN401) 181 (47 to 707), n=9 [median days, Full Range]
- PFS · Progression-free Survival (PFS)
- Treatment (APN401) 70 (47 to 237), n=9 [median days, Full Range]
Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This phase I trial studies the side effects and best dose of APN401 in treating patients with pancreatic cancer, colorectal cancer, or other solid tumors that have spread to other places in the body or have come back. APN401 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Detailed description public domain (ClinicalTrials.gov)
PRIMARY OBJECTIVES: I. To determine the toxicities and establish the safety of multiple infusions of small interfering ribonucleic acid (siRNA)-transfected peripheral blood mononuclear cells APN401 (APN401). SECONDARY OBJECTIVES: I. To determine the immunologic effects of multiple infusions of APN401. II. To document clinical response and survival. OUTLINE: Patients receive siRNA-transfected peripheral blood mononuclear cells APN401 intravenously (IV) over 30 minutes on days 1, 29, and 57 in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 5 years.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Number of Adverse Events Common Terminology Criteria for Adverse Events Version 4.0 [Up to 1 year]. Count Of Participants, Participants. General disorders and administration site conditions / Unobserved: Treatment (APN401) (n=9): 0. General disorders and administration site conditions / Grade 1: Treatment (APN401) (n=9): 1. General disorders and administration site conditions / Grade 2: Treatment (APN401) (n=9): 8. General disorders and administration site conditions / Grade 3: Treatment (APN401) (n=9): 0. Nervous System Disorders / Unobserved: Treatment (APN401) (n=9): 5. Nervous System Disorders / Grade 1: Treatment (APN401) (n=9): 4. Nervous System Disorders / Grade 2: Treatment (APN401) (n=9): 0. Nervous System Disorders / Grade 3: Treatment (APN401) (n=9): 0. Gastrointestinal Disorders / Unobserved: Treatment (APN401) (n=9): 6. Gastrointestinal Disorders / Grade 1: Treatment (APN401) (n=9): 2. Gastrointestinal Disorders / Grade 2: Treatment (APN401) (n=9): 0. Gastrointestinal Disorders / Grade 3: Treatment (APN401) (n=9): 1. Musculoskeletal and connective tissue disorders / Unobserved: Treatment (APN401) (n=9): 7. Musculoskeletal and connective tissue disorders / Grade 1: Treatment (APN401) (n=9): 0. Musculoskeletal and connective tissue disorders / Grade 2: Treatment (APN401) (n=9): 2. Musculoskeletal and connective tissue disorders / Grade 3: Treatment (APN401) (n=9): 0.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Clinical Response as Assessed by RECIST [Up to approximately 4 years]. Count Of Participants, Participants. Complete Response: Treatment (APN401) (n=9): 0. Partial Response: Treatment (APN401) (n=9): 0. Stable Disease: Treatment (APN401) (n=9): 3. Progressive Disease: Treatment (APN401) (n=9): 6.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Frequency of Immune Cells [Days 15 and 28]. Mean, percentage of cells (Standard Deviation). CD3+ (day 15): Treatment (APN401) (n=9): 37.1 (17.3). CD3+ (day 28): Treatment (APN401) (n=9): 40.3 (15.1). CD4+ (day 15): Treatment (APN401) (n=9): 19.0 (20.0). CD4+ (day 28): Treatment (APN401) (n=9): 26.4 (4.0). CD8+ (day 15): Treatment (APN401) (n=9): 15.5 (16.1). CD8+ (day 28): Treatment (APN401) (n=9): 22.7 (14.1). CD14+ (day 15): Treatment (APN401) (n=9): 5.1 (2.8). CD14+ (day 28): Treatment (APN401) (n=9): 7.3 (7.3). CD19+ (day 15): Treatment (APN401) (n=9): 1.2 (1.6). CD19+ (day 28): Treatment (APN401) (n=9): 2.6 (3.2). CD45RO+ (day 15): Treatment (APN401) (n=9): 14.8 (8.2). CD45RO+ (day 28): Treatment (APN401) (n=9): 37.3 (2.0). CD56+ (day 15): Treatment (APN401) (n=9): 4.8 (3.4). CD56+ (day 28): Treatment (APN401) (n=9): 8.3 (8.5). CD4+ICOS+ (day 15): Treatment (APN401) (n=9): 12.8 (19.7). CD4+ICOS+ (day 28): Treatment (APN401) (n=9): 16.8 (15.7). CD4+CD45RO+ (day 15): Treatment (APN401) (n=9): 14.8 (8.2). CD4+CD45RO+ (day 28): Treatment (APN401) (n=9): 37.3 (2.0). CD4+FOXP3+ (day 15): Treatment (APN401) (n=9): 13.9 (16.4). CD4+FOXP3+ (day 28): Treatment (APN401) (n=9): 29.5 (18.3). CD8+ICOS+ (day 15): Treatment (APN401) (n=9): 12.3 (14.5). CD8+ICOS+ (day 28): Treatment (APN401) (n=9): 25.2 (7.8). CD3-CD56+ (day 15): Treatment (APN401) (n=9): 4.2 (1.7). CD3-CD56+ (day 28): Treatment (APN401) (n=9): 5.4 (1.1).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Immune Response as Measured by Interferon Production [Days 15 and 28]. Mean, pg/ml (Standard Deviation). IFN (day 15): Treatment (APN401) (n=9): 75.1 (17.6). IFN (day 28): Treatment (APN401) (n=9): 90.7 (37.8). IL-2 (day 15): Treatment (APN401) (n=9): 226 (51.1). IL-2 (day 28): Treatment (APN401) (n=9): 674.4 (978.6).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Neutrophil to Lymphocyte Ratio [Days 15 and 28]. Mean, ratio (Standard Deviation). Day 15: Treatment (APN401) (n=9): 2.72 (1.21). Day 28: Treatment (APN401) (n=9): 4.98 (5.81).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Overall Survival (OS) [From the initial infusion to confirmation of death, assessed up to approximately 4 years]. Median, days (Full Range). Treatment (APN401) (n=9): 181 (47 to 707).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Progression-free Survival (PFS) [From the initial infusion to confirmation of progression or death, assessed up to approximately 4 years]. Median, days (Full Range). Treatment (APN401) (n=9): 70 (47 to 237).